Leary investors
17 September 2020

Compass Pathways, which treats depression with a psilocybin-based compound, is raising $107 mln. It has no revenue. Its risk factors are like a bad trip. But as investors throw cash at blank-cheque firms promising visions of the future, taking a punt doesn’t seem so risky.